|
|
 |
 |
| |
 Printable version |
Evaluation of the protocol CMA reinforced in the treatment of endemic Burkitt lymphoma at CHU of Yopougon in Abidjan |
Bulletin du Cancer. Volume 97, Number 5, 507-9, mai 2010, Article original
|
 Résumé
Article gratuit
|
Author(s) : A Tolo-Diebkilé, GK Koffi, CD Nanho, D Sawadogo, B Kouakou, L Siransi-Bogui, R Ayémou, I Sanogo |
Summary : We report the results of the protocol CMA (cyclophosphamide, methotrexate, Aracytine
®) reinforced of 26 patients affected by Burkitt lymphoma in facial-maxillary localisation, in a retrospective study from January 2000 till December 2007 and prospective from January till September 2008. Their average age was 7.89 years, with a sex ratio of 2.71. The global response to the treatment was 92.3% with 57.7% of complete remission and 34.6% of incomplete remission. The morbidity related to treatment was essentially a haematological complication (84.6%) and hydroelectrolytic complication (84.6%). Evolution was made towards death in 30.8 and 15.4% were lost of view. The median monitoring was 18.2 months. Treatment response was linked to the therapeutic compliance (P <\; 0.001), and the delay of consultation (P \= 0.01). |
Keywords : Burkitt, facial-maxillary localisation, treatment |
|
